Here is some "GENERAL OVERVIEW INFORMATION" on ADOT...
PLEASE NOTE: This may take a while to read, but I find it to be some of the Most Amazing and Verifiable information I have seen. This is truly exciting to me!
(This information has been compiled by me, an independent investor, and is presented to be as accurate as possible according to what information I have been able to obtain from public and private sources. This should NOT be assumed exact, but is presented as a starting point for research purposes.)
Ticker Symbol: ADOT (OTC:BB)
COMPANY:
Advanced Optics Electronics, Inc
5601 Holly NE
Albuquerque, NM 87113
Phone: 505-797-7878
Fax:: 505-858-1871
CEO: Leslie Robins
PATENTED TECHNOLOGY Unites ELECTRONICS with CANCER RESEARCH.
WEB SITE: adot.org
WEB SITE for BIOMODA: biomoda.com
RECENT PRESS RELEASES:
quote.yahoo.com
SEC STATUS:
ADOT is filing to be a fully reporting company with the SEC.
TOTAL SHARES AUTHORIZED: 25 million
TOTAL SHARES OUTSTANDING: 7,155,503 (12-31-97 Fin Stmt)
SHARES IN THE FLOAT: Apx 2 million
EARNINGS:
1997 EPS: (.01) Note! They were a developmental stage company in 1997!
1998 is expected to be profitable.
Click Here for 1997 Balance Sheet
adot.org
Click Here for 1997 Income Statement
adot.org
Click Here for 1997 Cash Flow Statement
adot.org
REVENUE ESTIMATES:
1998 sales of $4.4 Million from Flat Panel Displays (NOT including BIOMODA)
1999 sales of $12.0 Million from Flat Panel Displays (NOT including BIOMODA)
Estimates from BIOMODA are (conservatively) $9 Million in revenue in the third year of commercial administration and $70 Million or more in the fifth year.
Profit margins from BIOMODA are expected to be very, very large!
GENERAL BUSINESS INFORMATION:
ADOT's unique profit potential can be derived from 2 compatible sources...
Profits from Flat Panel Displays and
Profits from BIOMODA Early Cancer Detection and Treatment.
Patented Technology is the link between the Flat Panel Displays and the BIOMODA Early Cancer Detection and Treatment.
1)
FLAT PANEL DISPLAYS:
Advanced Optics Electronics, Inc (ADOT) is primarily an electro-optic technology company that designs and produces large scale (14' x 42') flat panel displays for the outdoor advertising industry using a patented technology. The displays will create billboards that more closely resemble large television screens.
ADOT's displays provide crisp images with superior speed and image quality. The Company's turnkey package can create and control billboard graphics from a remote terminal via satellite thus enabling advertisers to sell billboard ad time in blocks similar to TV and radio.
In addition to regular ads, advertisers can also tailor messages for short-term markets such as morning drive-time commuters, up-coming events, etc.
These billboards are designed for new installations and conversions of existing units in the $2.3 Billion outdoor advertising industry. The industry is growing rapidly. Demand is exploding and advertising rates are steadily increasing.
Billboards are highly cost-effective and are usually priced 80% less than TV, 70% less than print media, and 50% less than radio.
The first contract is for $1.7 Million. Delivery was originally set for Jan 98. However, the Buyer has requested modifications and delivery is now set for April 1998.
2)
BIOMODA EARLY CANCER DETECTION & TREATMENT:
(ADOT owns 20% or more of BIOMODA)
BIOMODA Inc. is a bio tech company that holds a world-wide exclusive license in perpetuity from the University of California to a NEW patented molecular marker/binder technology for the very early detection of lung cancer AND an integrated treatment for lung cancer.
ADOT is positioned to benefit from this because BIOMODA's patented medical technology incorporates the patented electronics technology ADOT uses in flat panel displays.
Specifically, BIOMODA incorporates this technology in the equipment it uses for early cancer detection and treatment of lung cancer.
BIOMODA has an exclusively licensed synthetic TCPP (a photoreactive porphyrin compound) that is rapidly absorbed by cancer cells, particularly lung cancer cells. One of the important characteristics of TCPP is that it fluoresces red when exposed to ultraviolet light. Current methods of cytological detection depend on human visualization and subjective interpretation or pattern recognition to locate abnormal cells.
Click Here to see a demonstration of how this technology works:
biomoda.com
Wide scale application of BIOMODA's technology requires standardization and automation of readings. The patented technology ADOT uses can provide the image analysis automation necessary for large-scale screening in cytopathology labs across the country and around the world.
This technology was originally used in research done by the government at Los Alamos & Sandia Laboratories and involved researchers from both BIOMODA and ADOT.
BIOMODA has given ADOT the first right of refusal to design, manufacture and distribute the scanning test devices used for the lung cancer tests. The BIOMODA tests detect lung cancer 6 years earlier than all other tests currently used.
Consequently, ADOT recently acquired a substantial minority interest in BIOMODA (20% or more).
BIOMODA estimates there are 77 million Americans over age 45 who are at risk of lung cancer. In 1991, an estimated 25 percent smoked. That represents at least 19 million people who might benefit from an annual screening for lung cancer (similar to the screening for cervical cancer in women after puberty).
The early detection cancer test can be expected to improve 5-year survival rates from 13% up to 46%. With the advent of Biomoda's new lung cancer treatment, this diagnostic/treatment program can be expected to increase these survival rates even further.
For Lung Cancer Screening - At $100 per test, the potential annual market just for all smokers over age 45 is $1.9 Billion! For all smokers over the age of 40, it's $3 Billion !!
For Lung Cancer Treatment - BIOMODA estimates the present market for lung cancer therapies is about $450 Million and BIOMODA expects to retain a significant share of that market.
SUMMARY:
So ADOT can benefit from BIOMODA's program in 2 ways as follows:
1. ADOT has the first right of refusal to design, manufacture and distribute the scanning test devices used for the lung cancer tests.
2. ADOT owns 20% or more of BIOMODA, Inc. BIOMODA profits will directly benefit ADOT and subsequently ADOT shareholders.
RESEARCH CREDENTIALS:
Research on both the early cancer detection test and the proprietary imaging and treatment program was conducted at:
Los Alamos National Laboratories in New Mexico, the University of New Mexico at Albuquerque, and St. Mary's Hospital and Medical Center in Grand Junction, Colorado.
Public testing of this research will soon begin at a respected cytopathology lab in Scottsdale, Ariz.
SCIENTIFIC ADVISORY BOARD Includes Noted Leader in Lung Cancer Research:
Geno Saccomanno, M.D., Ph.D. of St. Mary's Hospital and Medical Center in Colorado.
Dr Saccomanno is considered "the world's best pulmonary cyto-pathologist."
emphysemafoundation.org
Dr Saccomanno is one of the most highly respected lung cancer researchers in the world.
He has been actively involved in lung cancer research for over 40 years and is most noted for his lung cancer research involving uranium miners throughout Colorado. He works closely with the US Dept of Justice and the US Dept of Energy.
Here are a few more sites that reflect his work.
agi.umd.edu
aacr.org
aacr.org
niehs.nih.gov
columbia.net
uchsc.edu
eml.doe.gov
ehpnet1.niehs.nih.gov
biomoda.com
Here are the bios on the Scientific Advisory Board for Biomoda:
biomoda.com
OTHER CONSIDERATIONS:
$1 million financing in 8% convertible subordinated debentures with an 18 month restricted term was completed in October, 1997. The restriction does not expire until April, 1999. The financing was arranged with a non-U.S. investor. Proceeds will be used for working capital as well as the Company's pending acquisition of a space and information technologies development firm, as announced on July 8, 1997.
BIOMODA's immediate goal for the U.S. is to market sputum sample cytopathology reagent kits using TCPP, a lung cancer in vivo diagnostic product, and a lung cancer therapeutic product.
Advanced Optics Electronics, Inc. is also continuing negotiations with the previously announced space and information technologies company. The space and information technologies company is estimated to generate minimum revenues of $8 million a year over the next five years with $10 million in backlog orders. The firm services a broad
customer base including the U.S. Air Force, Boeing, Lockheed Martin, Honeywell, Department of Defense, Department of Energy, Federal Aviation Administration, Sandia and Los Alamos National Laboratories, and the Veterans Administration.
ADOT also announced recently that preliminary discussions have begun with Literal Corp for the acquisition of certain patents and a possible equity interest in Literal. Literal Corp holds numerous patents relating directly and indirectly to data transmission and
compression for optically sensed and transmitted information.
TALK FORUMS:
Silicon Investor Subject 16128
TODAY'S QUOTE:
(Type "ADOT" in the "Real Time" box)
freerealtime.com:8001/
or 15-minute delayed with news:
quote.yahoo.com
CHART:
tscn.com
HISTORICAL PRICING: (Type the "ADOT" in the Symbol box)
tradepbs.com
INSIDER BUYING / SELLING REPORTS: insidertrader.com
WHY I LIKE THIS COMPANY:
1. Small Float
2. Profit potential from Flat Panel Displays
3. Enormous Profit potential from BIOMODA.
4. The BIOMODA early lung cancer detection and treatment is amazing!
4. Cancer research & treatment claims are verifiable!
5. The BIOMODA position and the acquisitions under consideration all appear to enhance ADOT's posture in it's primary market.
6. I see a strong possibility that the BIOMODA interest could be acquired by a major medical or pharmaceutical firm.
PLEASE NOTE:
I am NOT associated with this company in any way. I am an individual investor with my own opinions. I don't give advice. Questions should be directed to the appropriate source, many of which are listed above. Everyone is urged to do their own research before investing in anything.
Best wishes,
Brad |
